TAZAROTENE
Clinical safety rating: avoid
Contraindicated (not allowed)
Tazarotene is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity, modulating gene expression involved in cell proliferation, differentiation, and inflammation.
| Metabolism | Tazarotene is rapidly metabolized by esterases to its active metabolite, tazarotenic acid. Further metabolism occurs via hydroxylation, oxidation, and conjugation (glucuronidation), primarily in the liver. |
| Excretion | Primarily fecal (approximately 60%) and urinary (approximately 13%) as metabolites; unchanged drug not detected in urine. |
| Half-life | Terminal elimination half-life of tazarotenic acid is 7–12 hours in healthy subjects; clinically, steady-state is achieved within 14 days. |
| Protein binding | Tazarotenic acid is >99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Apparent volume of distribution for tazarotenic acid is approximately 2.1 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Topical: systemic absorption is minimal (<1% of applied dose under normal conditions); oral not formulated for systemic use. |
| Onset of Action | Topical: improvement in acne within 4 weeks; for psoriasis, noticeable reduction in scaling and erythema within 2–4 weeks. |
| Duration of Action | Topical: therapeutic effects persist for several weeks after cessation; in psoriasis, remission may last up to 3 months. |
| Molecular Weight | 351.57 Da |
Topical: Apply a pea-sized amount to affected areas once daily in the evening. For plaque psoriasis, use 0.05% or 0.1% gel or cream. For acne vulgaris, use 0.1% cream or 0.045% or 0.1% lotion.
| Dosage form | GEL |
| Renal impairment | No dose adjustment required for topical use. Systemic absorption is minimal; no specific GFR-based guidelines available. |
| Liver impairment | No dose adjustment required for topical use. Systemic absorption is minimal; no specific Child-Pugh based guidelines available. |
| Pediatric use | Approved for acne vulgaris in patients ≥12 years: apply a pea-sized amount of 0.1% cream or 0.045% or 0.1% lotion once daily. For plaque psoriasis, safety and efficacy not established in pediatric patients <18 years. |
| Geriatric use | No specific dose adjustments; use caution due to potential increased skin fragility and reduced renal/hepatic function. Monitor for local adverse reactions. |
| 1st trimester | Contraindicated. Topical tazarotene is a retinoid with teratogenic potential; systemic exposure is low but should not be used during pregnancy due to risk of fetal harm. |
| 2nd trimester | Contraindicated. Avoid use during second trimester; retinoids can cause fetal abnormalities. |
| 3rd trimester | Contraindicated. Avoid use during third trimester; systemic absorption may pose risk to fetus. |
Clinical note
No significant drug interactions Highly teratogenic females must use effective contraception.
| Placental transfer | Unknown degree; but as a retinoid, systemic exposure is low due to minimal transdermal absorption; however, theoretical risk exists. |
| Breastfeeding | Topical application likely results in minimal systemic absorption; however, due to limited data and potential for transfer to infant, caution is advised. Avoid application to breast area. Consider alternative treatments if breastfeeding. |
■ FDA Black Box Warning
Tazarotene is contraindicated in women who are or may become pregnant. Exposure during pregnancy is associated with a high risk of severe birth defects, similar to other retinoids.
| Common Effects | Nausea Vomiting Diarrhea Rash Allergic reaction |
| Serious Effects |
PregnancyHypersensitivity to tazarotene or any component of the formulation
| Precautions | Avoid use during pregnancy; effective contraception required for women of childbearing potential., Photosensitivity: advise sun protection and avoid sunlamps., Local skin reactions: burning, stinging, erythema, peeling, pruritus; reduce frequency or concentration if severe., Avoid application on eczematous or sunburned skin., Potential for increased absorption with concurrent dermal irritation or use on large body surface areas., Not recommended for use on intertriginous areas. |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L3 - Limited Data |
| Teratogenic Risk | Tazarotene is a topical retinoid contraindicated in pregnancy (Category X). Systemic absorption is minimal (~1-6%) but teratogenic risk exists; fetal exposure can cause retinoid-like malformations including CNS, cardiovascular, and craniofacial defects. Avoid in pregnant women or those planning pregnancy. If pregnancy occurs during use, immediate discontinuation is advised. |
| Fetal Monitoring | Monitor for signs of teratogenicity if inadvertent pregnancy exposure occurs. No specific monitoring required beyond standard pregnancy surveillance. |
| Fertility Effects | No human data on fertility effects. Animal studies show no impairment at systemic exposures comparable to human topical use. |
| No significant food interactions. Avoid excessive vitamin A supplements due to additive retinoid effects. |
| Clinical Pearls | Tazarotene is a topical retinoid used for psoriasis and acne; avoid application to eczematous or sunburned skin; combine with emollients to reduce irritation; may increase photosensitivity, advise sun protection; contraindicated in pregnancy (Pregnancy Category X); apply only a thin layer to affected areas; avoid use on large body surface areas in patients with liver or kidney impairment due to systemic absorption; for psoriasis, consider short-contact therapy to reduce irritation. |
| Patient Advice | Apply only to affected areas, avoiding healthy skin. · Use a pea-sized amount for acne; do not apply more than directed. · Wash hands after application unless treating hands. · Expect mild burning, stinging, or peeling initially; use moisturizer. · Avoid sun exposure and use sunscreen daily. · Do not use if pregnant, planning to become pregnant, or breastfeeding. · Avoid other irritating topical products (e.g., astringents, exfoliants). · Do not apply to broken, eczematous, or sunburned skin. · Improvement may take 2–4 weeks for acne, 4–12 weeks for psoriasis. · Discontinue if severe irritation or allergic reaction occurs. |